Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Wang, Guanyun; Zhang, Wenwen; Luan, Xiaohui; Wang, Zhanbo; Liu, Jiajin; Xu, Xiaodan; Zhang, Jinming; Xu, Baixuan; Lu, Shichun; Wang, Ruimin; Ma, Guangyu

doi:10.3389/fimmu.2023.1219757

CORRECTION article

Front. Immunol. , 22 May 2023

Sec. Cancer Immunity and Immunotherapy

Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1219757

This article is part of the Research Topic Novel Biomarkers in Tumor Immunity and Immunotherapy View all 49 articles

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

This article is a correction to:

The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
1. Read original article

Guanyun Wang^1,2†

Wenwen Zhang^3†

Xiaohui Luan^1,4

Zhanbo Wang⁵

Jiajin Liu¹

Xiaodan Xu¹

Jinming Zhang¹

Baixuan Xu¹

Shichun Lu^3*

Ruimin Wang^1*

Guangyu Ma^1*

¹Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
²Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China
³Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China
⁴Graduate School, Medical School of Chinese People’s Liberation Army (PLA), Beijing, China
⁵Department of Pathology, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China

A corrigendum on
The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

by Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023). Front. Immunol. 14:1151967. doi: 10.3389/fimmu.2023.1151967

In the published article, there was an error in the formula in the manuscript.

A correction has been made to Materials and Methods, Image analysis, Paragraph 2. This sentence previously stated:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

Δ SUVmax (%) = \frac{SUVmax of pre-treatment - SUVmax of post-treatment}{SUVmax of pretreatment} \times 100 %

ΔTLR (%) = \frac{TLR of pre-treatment - TLR of post-treatment}{TLR of pre-treatment} \times 100 %

ΔPLR (%) = \frac{PLR of pre-treatment - PLR of post-treatment}{PLR of pre-treatment} \times 100 % ”

The corrected sentence appears below:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

Δ SUVmax (%) = \frac{SUVmax of post-treatment - SUVmax of pre-treatment}{SUV of pre-treatment} \times 100 %

ΔTLR (%) = \frac{TLR of post-treatment - TLR of pre-treatment}{TLR of pre-treatment} \times 100 %

ΔPLR (%) = \frac{PLR of post-treatment - PLR of pre-treatment}{PLR of pre-treatment} \times 100 % ”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: unresectable hepatocellular carcinoma, conversion therapy, major pathological response, prognosis, ¹⁸F-FDG PET

Citation: Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023) Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy. Front. Immunol. 14:1219757. doi: 10.3389/fimmu.2023.1219757

Received: 09 May 2023; Accepted: 12 May 2023;
Published: 22 May 2023.

Edited and Reviewed by:

Takaji Matsutani, Repertoire Genesis, Inc., Japan

Copyright © 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Guangyu Ma, bWd5MzAxQDE2My5jb20=; Ruimin Wang, d3JtQHllYWgubmV0; Shichun Lu, bHVzY18zMDFAMTYzLmNvbQ==

^†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Publisher’s note

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good